Jubilant Ingrevia inks pact to acquire 100% stake in Remidex Pharma
Cost of acquisition is Rs 16.5 crore subject to customary closing conditions
Jubilant Ingrevia has entered into the Share Purchase Agreement with Remidex Pharma (Remidex) for acquisition of its 100% stake. After acquisition Remidex will become wholly owned subsidiary of the Company.
This acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition Space building upon its leadership position in Vitamins (Vitamin B3 & B4). Cost of acquisition is Rs 16.5 crore subject to customary closing conditions. The said acquisition is expected to be completed in 30 days.
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers.
